Morning everyone!! I just received the following information...

Morning everyone!!

I just received the following information about CDX & CDXO - so thought that I would share it with you good folk

Hopefully it "copies and pastes" OK - as it provides a really good summary of this business (see below):

CARDIEX LTD (CDX) Option Conversion - Expiry Tuesday, 30 November 2021


Market price (last 20min): 0.073
Your 30 Nov 2021 Exercise price: 0.05 + no brokerage.

'Optionholder Q&A' is located at the bottom of this email.

CARDIEX LIMITED (CDX) has authorised us to contact their optionholders on their behalf to ensure you have received your Option Conversion Information via email/or post.

The Company is providing eligible optionholders (such as yourself) the opportunity to convert your CDX Options before expiry (expiring 30 November 2021) into fully paid ordinary shares at an exercise price of $0.05. All converted options will provide CardieX with $8.16m in additional working capital.

All directors who hold CDXO and other unlisted options expiring 30 November 2021 intend to exercise their Options before the expiry to the full capacity (see announcements dated 25.10.2021). On this basis, CardieX expects to raise a minimum of $1.5m from the exercise of Director held Options.

Given the tight expiry window, we’re contacting you today to make sure you’re aware of your ability to participate and convert your options into shares as an eligible option holder in the business.

How to exercise your CDXO 30 Nov 2021 options

Payments can be made by Electronic Funds Transfer (EFT):
Account Name: Cardiex Limited
BSB: 082 356
Account: 787999697
Reference: Include your surname
Also complete the conversion form which can be downloaded here - Form Download Link
Payment must be received BEFORE 5:00pm (AWST) Tuesday, 30 November 2021 (“Expiry Date”.

For further questions relating to the offer, or making payment please contact Stevan Adzic (Peloton Shareholder Services). – 0401 639 114 or email [email protected]


Proceeds from all option conversions will provide the company with $8,164,704 in available working capital, intended to primarily be used to support identified growth initiatives in the business.

Ultimately the proceeds will place CardieX in a strong position to capitalise on their commercialisation strategy as highlighted below and realise their value-add proposition for customers and shareholders.

Investment Highlights since January 2021 include:

• Significant progress in 2021 with a major corporate restructure and launch of the new consumer health brand – CONNEQT, to focus on the Company’s new range of consumer devices which are set to transform the market opportunities for the Company.
• Under the CONNEQT brand, CardieX is on track to launch multiple new devices and digital products to the market over the next twelve months – One of the key differentiating features for the CONNEQT brand and its products will be the ability to provide medically reliable data unlike existing consumer wearable products such as Apple and Fitbit. The Company will also be seeking 510K clearance from US FDA – which the Company believes will be a key adoption driver for consumers and the medical industry more broadly.
• The Company is preparing for commercial launch of its new consumer devices and has recently appointed Fenda as their manufacturing partner for the CONNEQT Band wearable, for an initial 3-year term. Fenda is a leading Chinese manufacturer of smart wearable products. The agreement will also extend to other devices currently in development by the Company.
• CardieX and Mobvoi (Google-backed tech company) are also preparing for the imminent commercial launch of a new smartwatch with first-in-class, advance heart health features developed by CardieX’s 100% owned subsidiary – ATCOR, utilising their FDA-cleared SphygmoCor® technology. This is a major leap forward in CardieX’s commercialisation strategy.

In discussions with the company, we believe there are additional positive factors to consider:

• The foundation business, ATCOR, continues to experience good growth in traditional medical markets, with key customers, like Bayer AG, continuing to expand clinical trial work with the Company. This provides important validation for CardieX’s unique technology capabilities.

• After many years in development, the Company is set to leverage its proven abilities in the clinical trials, research & specialist medical setting and launch multiple new products in the much larger consumer and primary care (General Practitioner) markets, leveraging the Company’s core FDA-cleared SphygmoCor® technology and the more recent PPG sensor technology that will form a key part of the Company’s consumer strategy.

• Several important milestones over the coming 12-month period, with FDA clearances set to drive new product launches –
  • the first one is the CONNEQT Pulse device – which will be the world’s first “dual blood pressure” monitor available for consumers and primary care health professionals looking to access clinician-grade diagnostics for their health management.
  • The second is the CONNEQT Band – which on launch will, in CardieX’s opinion, be the world’s first AI-powered, FDA-cleared, clinical-grade smart health wearable featuring the company’s unique dual-PPG sensing technology.

• Following the launch of the Pulse device, the Company plans to launch a supporting digital health ecosystem to enable remote patient monitoring via the Company’s proprietary Arty™ platform which will have the potential to generate significant SaaS-based revenues for the Company when deployed.

• CardieX has a highly experienced Board and Management Team, with extensive hands-on operational experience in health technology, strategic business growth, and a wide collective of industry experience in Australia, the USA and around the world.

• CEO, Craig Cooper, is based in the USA and has a track record of founding and investing in multiple successful health, digital media, technology and consumer orientated businesses. He co-founded Boost Mobile in the USA and his prior VC firm funded and helped build multiple billion-dollar companies.
• Executive Chairman Niall Cairns is Sydney based and has a 25-year track record of value creation, restructuring, and exits in both listed and unlisted companies, having assisted in driving the global growth of over 50 companies in sectors as diverse as digital media, agtech, medtech, consumer Internet, and SaaS based businesses. Companies include Tru-Test ($148m sale), GMD, Gale (AVCAL award winner) and US based Harri.
• NED, King Nelson, is a 30 year veteran of the US medical industry commencing with Baxter and American Hospital Supplies before becoming a successful serial entrepreneur and CEO of VC backed companies in the US.

• Directors have skin in the game and will exercise their director-held options, expecting to raise a minimum of $1.5m. Furthermore, they have invested considerable amounts of their own money (c.$5m+) via direct share purchases/placements and are fully committed to the technology and motivated to ensure its success. CardieX’ major shareholder C2 Ventures (>20%) is equally owned by Niall Cairns (Chairman) and Craig Cooper (CEO). Directors have recently been granted significant performance shares to provide incentive and align with shareholder interests.

• Reflecting strong investor demand and growingly positive investor sentiment CardieX has seen its share price appreciate over 36% from Oct 2020 to Oct 2021. (Please note though that past share price performance is not indicative of any future price movement as prices may fall or rise in the future).

CARDIEX LIMITED (CDX) is a global health technology company. Its ACTOR subsidiary is a world leader in medical devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders based upon its SphygmoCor® technology, which is FDA cleared and is the industry “gold standard”. Its CONNEQT subsidiary develops and markets consumer home health devices and wearables. CardieX is listed on the Australian Stock Exchange

Currently there are more than 4,500 SphygmoCor® systems in use worldwide at major medical institutions, research institutions, and in various (current) clinical trials with leading pharmaceutical companies such as Bayer AG, and AstraZeneca.

The Company’s subsidiary, ATCOR, also licenses its medical and wearable technology to third parties. The Company’s Arty™ platform consists of physiological and health analytics for wearable devices and will be first incorporated in the upcoming Mobvoi watch partnership. Separately, ATCOR also licenses its SphygmoCor® technology to SunTech Medical, a global leader in medical devices.

The group manufacturing and R&D operations are located in Sydney. The American subsidiary, ATCOR Medical Inc., is headquartered in Naperville, Illinois. The CONNEQT subsidiary and executive offices are located in Newport Beach, California, and business development for Asian markets is located in Shanghai.


CardieX Optionholder Q&A

Question – How does it benefit me and the business by exercising my options?
You will be able to participate further value of the company via exercising your options to shares, and by exercising your options you will also be capitalising the company and assisting with expediting growth initiatives.

Question – What will CardieX do with funds received from exercised options?
Funding the go-to-market strategy of CardieX’s new product launches, including product launch expenses, marketing, sales and inventory & working capital. Plus, market development, product and technology development and funding the expansion of the team as the company grows.

Question – If I don’t exercise my options, can I sell or transfer them? How do I do that?
The options are listed on the ASX, under the code CDXO. Your broker or online broker (Westpac, commsec) can facilitate this process if you decide to sell.

Question – What happens if I don’t exercise my options?
They expire worthless.

Question – When does CardieX anticipate the launch and full commercialisation with their Mobvoi smartwatch?
The launch of the Mobvoi/CardieX smartwatch is in US & Australia and is imminent as per recent press reports and media.

Question - What patents and approvals (FDA etc) has the company received for CY2021? What new approvals are pending to be received?
The company received a European patent in 2021, was granted a provisional patent and an expanded provisional patent in the USA relating to our PPG-sensor technology and is expected to imminently lodge a number of new applications for FDA clearance for new products in late 2021

Question - Are directors’ interests still aligned with shareholders' re/performance?
Since joining and repositioning CardieX over the last 4 years, the directors have invested >$5m in new equity. In addition, shareholders have approved significant performance share rights to directors (including at the December 2020 AGM) at share prices of up to $0.50 cps. This provides a significant incentive to all directors, especially the executive directors, and significantly aligns with shareholder interests. Niall Cairn’s (Executive Chairman), and Craig Cooper, (CEO), are the company’s largest shareholders.

Question – What does CardieX’s strategic commercialisation timeline look forward for the next 6 months?
In the next 6 months, the company is focused on lodging 2-3 new technology products/solutions for FDA clearance, launching the CONNEQT Pulse, the world’s first “dual blood pressure monitor” (post FDA clearance), launching the Mobvoi/CardieX smartwatch, entering into new strategic alliances, making significant progress on CONNEQT products/solutions and further growing revenue.


How to exercise your CDXO 30 Nov 2021 options

Payments can be made by Electronic Funds Transfer (EFT):
Account Name: Cardiex Limited
BSB: 082 356
Account: 787999697
Reference: Include your surname
Also complete the conversion form which can be downloaded here - Form Download Link
Payment must be received BEFORE 5:00pm (AWST) Tuesday, 30 November 2021 (“Expiry Date”.

For further questions relating to the offer, or making payment please contact Stevan Adzic (Peloton Shareholder Services). – 0401 639 114 or email [email protected]